Loading
SO
Shanghai Obio Technology (Group) Corp., Ltd. Stock: price and insider trades · China
和元生物
CN·Mcap CN¥4.5B
Shanghai Obio Technology (Group) Corp., Ltd.: what insiders have been doing
Insider filings for Shanghai Obio Technology (Group) Corp., Ltd. are scarce in the SSE / SZSE (CSRC) feed, the latest one published on 23 September 2026. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€10,961
1 ops. · all time
Who traded when
BuySale杨佳丽1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,681 of 23,476 companies
13.2
score / 100
Value21
Quality5
FCF yld-5.1%
Earn yld-5.3%
EV/EBITDA·
ROE-16%
Gross mgn-15%
Net mgn-88%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥6.89
Analyst consensus
1 analystsCN¥9.30Target CN¥9.30(+35%)CN¥9.30
Income statement
RevenueCN¥267.7M
Gross profit-CN¥38.9M-15% margin
EBITDA-CN¥127.4M-48% margin
Net income-CN¥235.1M-86.0% margin
Valuation
P/Book3.3x
Beta0.44
Balance sheet & cash
Market capCN¥4.5B
Total debtCN¥420.4M
Free Cash Flow-CN¥228.8M
Debt / Equity34%
Profitability & ownership
ROE-16.3%
ROA-6.7%
% insiders28.2%
% institutions9.6%
Last declaration on 23 September 2026
About Shanghai Obio Technology (Group) Corp., Ltd.
He Yuan Biotechnology is a company specializing in the biotechnology sector, focusing on research and development of innovative health solutions. It is listed on the Shanghai Stock Exchange.
